About
Publications
Download-
2024Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies, Pathogens and Immunity, 2024, 10 (1), pp.1-11. ⟨10.20411/pai.v10i1.752⟩.
-
2024Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2., iScience 2024 Jul; 27(7): 110354.
-
2024Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion., Nat Commun 2024 Mar; 15(1): 2254.
-
2023High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1., J Virol 2023 Dec; (): e0135123.
-
2023TMPRSS2 is a functional receptor for human coronavirus HKU1., Nature 2023 Oct; (): .
-
2023Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals., Cell Host Microbe 2023 Jun; 31(6): 937-948.e4.
-
2023Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies., Nat Commun 2023 Feb; 14(1): 824.
-
2022Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies., Cell Rep Med 2022 Nov; (): 100850.
-
2022Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection., Med (N Y) 2022 Dec; 3(12): 838-847.e3.
-
2022Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study., EClinicalMedicine 2022 Sep; 51(): 101576.
-
+View full list of publications